| Seq | Brand | Generic | Manufacturer | Product code | Model | Catalog | Lot | PMA | 510(k) | Implant | Evaluated | Availability |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MEDTRONIC NEUROMODULATION | MFR | NEU_INS_STIMULATOR | NEU_INS_STIMULATOR | UNKNOWN | * | N |
| Sequence | Received | Treatment | Outcome |
|---|---|---|---|
| 1 | 2016-12-16 | 0 | 1. L |
Patient 1
DATE OF EVENT: PLEASE NOTE THAT THIS DATE IS BASED OFF OF THE DATE OF PUBLICATION OF THE ARTICLE AS THE EVENT DATES WERE NOT PROVIDED IN THE PUBLISHED LITERATURE. A GOOD FAITH EFFORT WILL BE MADE TO OBTAIN THE APPLICABLE INFORMATION RELEVANT TO THE REPORT. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
Patient 1
POLOSAN, M., CHABARDES, S., BOUGEROL, T., ARDOUIN, C., POLLAK, P., BENABID, AL., KRACK, P. LONG-TERM IMPROVEMENT IN OBSESSIONS AND C OMPULSIONS WITH SUBTHALAMIC STIMULATION. NEUROLOGY. 2016;87(17):1843-1844. SUMMARY: OBSESSIVE-COMPULSIVE DISORDER (OCD) MAY BE CONCEPTUALIZED AS A DISORDER OF SELF-CONTROL AND BEHAVIORAL INHIBITION. RECENT STUDIES SUGGESTED INTEREST IN DEEP BRAIN STIMULATION (DBS) OF DIFFERENT SUBCORTICAL BRAIN TARGETS SUCH AS THE NUCLEUS ACCUMBENS, ANTERIOR INTERNAL CAPSULE/VENTRAL STRIATUM, AND SUBTHALAMIC NUCLEUS (STN) IN SEVERE, RESISTANT OCD. STN IS A CRITICAL NODE OF THE INDIRECT AND HYPERDIRECT BASAL GANGLIA? THALAMOCORTICAL CIRCUIT. STN-DBS MAY RELEASE ITS FUNCTION AS A BRAKE ON BEHAVIORAL PROGRAMS, DISINHIBITING HABITUAL RESPONSES AND ENABLING MORE FLEXIBLE GOAL-DIRECTED BEHAVIOR CONTROL IN OCD. LITTLE IS KNOWN ABOUT LONG-TERM OUTCOME OF STN-DBS IN OCD. BASED ON EXPERIENCE IN PARKINSON DISEASE, STN-DBS CAN INDUCE A CHANGE FROM APATHETIC TO DISINHIBITED BEHAVIOR. THIS TARGET HAS ALSO A POTENTIAL IMPACT ON ADDICTIONS. (B)(4). REPORTED EVENT: A (B)(6) MAN WITH BILATERAL SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION (STN-DBS) FOR THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER (OCD) OVERALL HAD A MAJOR IMPROVEMENT IN OCD, ANXIETY AND MOOD AND THEY WERE ABLE TO REINTEGRATE INTO THEIR SOCIAL, FAMILY AND WORK LIFE. THE PATIENT REPORTEDLY EXPERIENCED A MAJOR IMPROVEMENT IN PREEXISTING SUICIDAL IDEAS, BUT MADE 2 SUICIDAL ATTEMPTS ?IN A CONTEXT OF SHORT, PARTIAL RELAPSES? WHERE HE STOPPED TAKING HIS MEDICATION IN THE FIRST YEAR OF IMPLANT. ULTIMATELY AFTER 10 YEARS OF IMPLANT THE AUTHORS REPORTED ROBUST IMPROVEMENT THAT THE PATIENT SELF-ESTIMATED TO BE 80% COMPARED TO BASELINE. IT WAS NOT POSSIBLE TO ASCERTAIN SPECIFIC DEVICE INFORMATION FROM THE ARTICLE OR TO MATCH THE REPORTED EVENT WITH ANY PREVIOUSLY REPORTED EVENT.
Patient 1
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.